Protein Block Stops Vascular Damage in Diabetes
|
By HospiMedica International staff writers Posted on 24 Jun 2013 |
A new study demonstrates that the inhibition of a protein activated when blood sugar is raised suppresses accelerated atherosclerosis in diabetic mice.
Researchers at Lund University (Sweden) conducted a study in Streptozotocin (STZ)-induced diabetic in mice to investigate whether Nuclear Factor of Activated T-Cells (NFAT) activation may be a link between diabetes and atherogenesis, by measuring blood monocytes, endothelial activation, and inflammatory markers in the aorta, and proinflammatory cytokines in plasma. The study was initiated following previous studies that showed that hyperglycemia activates the transcription factor NFAT in the arterial wall, inducing the expression of the pro-atherosclerotic protein osteopontin.
The study showed that NFAT activation resulted in 2.2 fold increase in aortic atherosclerosis and enhanced proinflammatory burden. Subsequent in vivo treatment with the NFAT blocker A-285222 for four weeks completely inhibited the diabetes-induced aggravation of atherosclerosis, while having no effect in nondiabetic mice. The STZ-treated mice also exhibited hyperglycemia and higher plasma cholesterol and triglycerides, but these were unaffected by A-285222. In fact, the substance did not affect NFAT in any other cells or organs, ruling out systemic immunosuppression as the mechanism behind reduced atherosclerosis. The study was published in the June 3, 2013, issue of PLOS one.
“That is important. We don’t want to suppress the whole immune system. We also saw that the substance only has an effect when NFAT is active. The plaque formation was only stopped in diabetic mice and not in nondiabetic mice, which had normal blood sugar levels”, said lead author Anna Zetterqvist, MSc. “It appears that there are different mechanisms behind plaque formation caused by diabetes and not caused by diabetes.”
A wealth of epidemiologic evidence demonstrate that hyperglycemia promotes a widespread and aggressive form of atherosclerosis in the coronary arteries, lower extremities, and extracranial carotid arteries of diabetic patients, causing nearly 80% of all deaths and much of their disability. Both diabetes type 1 and type 2 are independent risk factors for myocardial infarction (MI), peripheral vascular disease (PVD), and stroke. In addition, recent studies also show a causal association between elevated glucose levels and increased carotid intima-media thickness, a marker of subclinical atherosclerosis.
Related Links:
Lund University
Researchers at Lund University (Sweden) conducted a study in Streptozotocin (STZ)-induced diabetic in mice to investigate whether Nuclear Factor of Activated T-Cells (NFAT) activation may be a link between diabetes and atherogenesis, by measuring blood monocytes, endothelial activation, and inflammatory markers in the aorta, and proinflammatory cytokines in plasma. The study was initiated following previous studies that showed that hyperglycemia activates the transcription factor NFAT in the arterial wall, inducing the expression of the pro-atherosclerotic protein osteopontin.
The study showed that NFAT activation resulted in 2.2 fold increase in aortic atherosclerosis and enhanced proinflammatory burden. Subsequent in vivo treatment with the NFAT blocker A-285222 for four weeks completely inhibited the diabetes-induced aggravation of atherosclerosis, while having no effect in nondiabetic mice. The STZ-treated mice also exhibited hyperglycemia and higher plasma cholesterol and triglycerides, but these were unaffected by A-285222. In fact, the substance did not affect NFAT in any other cells or organs, ruling out systemic immunosuppression as the mechanism behind reduced atherosclerosis. The study was published in the June 3, 2013, issue of PLOS one.
“That is important. We don’t want to suppress the whole immune system. We also saw that the substance only has an effect when NFAT is active. The plaque formation was only stopped in diabetic mice and not in nondiabetic mice, which had normal blood sugar levels”, said lead author Anna Zetterqvist, MSc. “It appears that there are different mechanisms behind plaque formation caused by diabetes and not caused by diabetes.”
A wealth of epidemiologic evidence demonstrate that hyperglycemia promotes a widespread and aggressive form of atherosclerosis in the coronary arteries, lower extremities, and extracranial carotid arteries of diabetic patients, causing nearly 80% of all deaths and much of their disability. Both diabetes type 1 and type 2 are independent risk factors for myocardial infarction (MI), peripheral vascular disease (PVD), and stroke. In addition, recent studies also show a causal association between elevated glucose levels and increased carotid intima-media thickness, a marker of subclinical atherosclerosis.
Related Links:
Lund University
Latest Critical Care News
- Painless Microneedle Skin Patch Monitors Immune Health

- Smart T-Shirt Uses AI to Enhance Detection of Heart Rhythm Disorders
- Aptamers Enable Real-Time Biomarker Tracking Without Blood Draws
- Specialized Dressing with Sensor Monitors pH Levels in Chronic Wounds
- AI Model Could Help Diagnose Spinal Cord Disease Up To 30 Months Earlier
- 3D-Printed Swallowable Robot Could Perform Gastrointestinal Procedures
- Next-Gen Hydrogel Could Transform Soft Tissue and Organ Repair
- Engineered Cancer Eating Bacteria Consume Tumors from Inside Out
- ‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes
- Smartphone-Linked Catheter Sensor Spots UTIs Sooner Than Lab Cultures
- AI Tool Identifies Trauma Patients Requiring Blood Transfusions Before Reaching Hospital
- New Clinical Guidelines to Reduce Central Line-Associated Bloodstream Infection
- New Inhalable Treatment for TB Lowers Side Effects
- AI Algorithm Improves Antibiotic Decision-Making in Urinary Tract Infection
- 3D-Printed System Enhances Vaccine Delivery Via Microneedle Array Patch
- Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias
Channels
Artificial Intelligence
view channelSurgical Techniques
view channel
Skull Implant Design Could Shape Surgical Outcomes
Cranioplasty is a common neurosurgical procedure performed to repair skull defects after decompressive craniectomy. In addition to restoring protection to the brain, the surgery can enhance neurological... Read more
Redesigned Surgical Laser Cuts Bone Deeper and Faster Than Before
Lasers are valued in surgery for their precision and non-contact cutting, reducing mechanical stress and minimizing microcracks. While widely used for soft tissue, their application in hard tissues such... Read more
Laser Ablation Plus Immunotherapy Improves Survival in Recurrent Glioblastoma
Recurrent high-grade astrocytoma, including glioblastoma, is difficult to treat and often returns after surgery. Patients with recurrence typically survive only four to five months, highlighting a critical... Read more
New Method Offers Less Invasive Detection of Susceptibility to Rare Anesthesia Reaction
Malignant hyperthermia (MH) is a rare, inherited reaction to general anesthetics that can be rapidly fatal without prompt recognition and treatment. Definitive preoperative testing today relies on an open... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read moreFirst-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Medtronic to Acquire Coronary Artery Medtech Company CathWorks
Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Medtronic and Mindray Expand Strategic Partnership to Ambulatory Surgery Centers in the U.S.
Mindray North America and Medtronic have expanded their strategic partnership to bring integrated patient monitoring solutions to ambulatory surgery centers across the United States. The collaboration... Read more
FDA Clearance Expands Robotic Options for Minimally Invasive Heart Surgery
Cardiovascular disease remains the world’s leading cause of death, with nearly 18 million fatalities each year, and more than two million patients undergo open-heart surgery annually, most involving sternotomy.... Read more







